Despite the use of the same PSMA PET/CT-based eligibility criteria as in prostate cancer patients to assess possible PSMA-RLT application, there are essential differences between prostate cancer and the solid cancers included in this review. The gene discussed is FOLH1; the disease is Familial prostate cancer.